Search

Your search keyword '"Balzer, Stefan"' showing total 22 results
Start Over Author "Balzer, Stefan"
22 results on '"Balzer, Stefan"'

3. Antimicrobial use in pediatric oncology and hematology in Germany and Austria, 2020/2021: a cross-sectional, multi-center point-prevalence study with a multi-step qualitative adjudication process

Author

Papan, Cihan, primary, Reifenrath, Katharina, additional, Last, Katharina, additional, Attarbaschi, Andishe, additional, Graf, Norbert, additional, Groll, Andreas H., additional, Hübner, Johannes, additional, Laws, Hans-Jürgen, additional, Lehrnbecher, Thomas, additional, Liese, Johannes G., additional, Martin, Luise, additional, Tenenbaum, Tobias, additional, Vieth, Simon, additional, von Both, Ulrich, additional, Wagenpfeil, Gudrun, additional, Weichert, Stefan, additional, Hufnagel, Markus, additional, Simon, Arne, additional, Baier, Jan, additional, Balzer, Stefan, additional, Behr, Ümmügül, additional, Bernbeck, Benedikt, additional, Beutel, Karin, additional, Blattmann, Claudia, additional, Bochennek, Konrad, additional, Cario, Holger, additional, Eggert, Angelika, additional, Ehlert, Karoline, additional, Göpner, Simone, additional, Kontny, Udo, additional, Körholz, Dieter, additional, Kramm, Christof, additional, Lauten, Melchior, additional, Lessel, Lienhard, additional, Linderkamp, Christin, additional, Lobitz, Stephan, additional, Maas, Volker, additional, Misgeld, Rainer, additional, Mücke, Urs, additional, Neubert, Jennifer, additional, Nonnenmacher, Lisa, additional, Queudeville, Manon, additional, Redlich, Antje, additional, Rodehüser, Martina, additional, Schober, Sarah, additional, Siepermann, Meinolf, additional, Simon, Thorsten, additional, Souliman, Hadi, additional, Stiefel, Martina, additional, Wiegering, Verena, additional, and Winkler, Beate, additional

Published
2023
Full Text
View/download PDF

6. Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea

Author

Allard, Pierre, Alhaj, Nareen, Lobitz, Stephan, Cario, Holger, Jarisch, Andreas, Grosse, Regine, Oevermann, Lena, Hakimeh, Dani, Tagliaferri, Laura, Kohne, Elisabeth, Kopp-Schneider, Annette, Kulozik, Andreas E., Kunz, Joachim B., Alashkar, Ferras, Singelmann, Carman Aramayo, Balzer, Stefan, Brecht, Ines, Brummel, Bastian, Classen, Carl Friedrich, Claviez, Alexander, Corbacioglu, Selim, Dilloo, Dagmar, Dürken, Matthias, Eberl, Wolfgang, Ebert, Sabine, Erlacher, Miriam, Escherich, Gabriele, Frühwald, Michael, Full, Hermann, Heine, Sabine, Hömberg, Marc, Holzapfel, Johannes, Holzer, Ursula, Khurana, Claudia, Kontny, Udo, Metzler, Markus, Nathrath, Michaela, Partheil, Anna, Pothoff, Claudia Maria, Prokop, Aram, Reinhard, Harald, Schenk, Daniela, Schneider, Dominik, Ströter, Natascha, and Wiesel, Thomas

Subjects
Drug, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, media_common.quotation_subject, Medizin, Pain, Anemia, Sickle Cell, Disease, Polymorphism, Single Nucleotide, Gastroenterology, Hydroxycarbamide, hemic and lymphatic diseases, Internal medicine, Fetal hemoglobin, medicine, Humans, Hydroxyurea, gamma-Globins, Globin, Allele, Fetal Hemoglobin, media_common, business.industry, Metalloendopeptidases, Hematology, medicine.disease, Hemolysis, Repressor Proteins, Red blood cell, medicine.anatomical_structure, Child, Preschool, business, medicine.drug
Abstract

The course of sickle cell disease (SCD) is modified by polymorphisms boosting fetal hemoglobin (HbF) synthesis. However, it has remained an open question how these polymorphisms affect patients who are treated with the HbF-inducing drug hydroxyurea/ hydroxycarbamide. The German SCD registry offers the opportunity to answer this question, because >90% of patients are treated according to national guidelines recommending the use of hydroxyurea in all patients above 2 years of age. We analyzed the modifying effect of HbF-related genetic polymorphisms in 417 patients with homozygous SCD >2 years old who received hydroxyurea. HbF levels were correlated with higher total hemoglobin levels, lower rates of hemolysis, a lower frequency of painful crises and of red blood cell transfusions. The minor alleles of the polymorphisms in the γ-globin promoter (rs7482144), BCL11A (rs1427407) and HMIP (rs66650371) were strongly associated with increased HbF levels. However, these associations did not translate into lower frequencies of vaso-occlusive events which did not differ between patients either carrying or not carrying the HMIP and BCL11A polymorphisms. Patients on hydroxyurea carrying the γ-globin promoter polymorphism demonstrated substantially higher hemoglobin levels (P

Published
2021
Full Text
View/download PDF

18. Digital Droplet PCR for Rapid Quantification of Donor DNA in the Circulation of Transplant Recipients as a Potential Universal Biomarker of Graft Injury

Author

Beck, Julia, primary, Bierau, Sarah, primary, Balzer, Stefan, primary, Andag, Reiner, primary, Kanzow, Philipp, primary, Schmitz, Jessica, primary, Gaedcke, Jochen, primary, Moerer, Onnen, primary, Slotta, Jan E, primary, Walson, Philip, primary, Kollmar, Otto, primary, Oellerich, Michael, primary, and Schütz, Ekkehard, primary

Published
2013
Full Text
View/download PDF

21. CCL3/MIP-1α Is a Potent Immunostimulator When Coexpressed with Interleukin-2 or Granulocyte-Macrophage Colony-Stimulating Factor in a Leukemia/Lymphoma Vaccine

Author

Zibert, Andree, Balzer, Stefan, Souquet, Manfred, Quang, Trong Hung, Paris-Scholz, Cristina, Roskrow, Marie, and Dilloo, Dagmar

Abstract

Chemokines orchestrate trafficking of immune effector cells during inflammation. Here we demonstrate that chemokines also serve to potentiate effector cell-mediated antineoplastic immune responses in vaccination strategies. As a critical mediator of inflammation, macrophage inflammatory protein 1α (CCL3/MIP-1α) attracts and stimulates both antigen-presenting and cytotoxic cells. In the A20 leukemia/lymphoma vaccine model, we explored the efficacy of MIP-1α in combination with interleukin-2 (IL-2) or granulocyte-macrophage colony-stimulating factor (GM-CSF). After subcutaneous injection of the MIP-1α + IL-2 or MIP-1α + GM-CSF combination vaccine, focal but pronounced infiltrates of CD4+ and CD8+ T cells were observed at the vaccination sites. In mice with preestablished leukemia/lymphoma, survival is significantly improved in animals treated with MIP-1α + GM-CSF- and MIP-1α + IL-2-secreting vaccines. Protection is superior in the MIP-1α + GM-CSF group, with the effects of MIP-1α and GM-CSF being synergistic. In contrast, suppression of lymphoblast proliferation by single-immunogen vaccines secreting MIP-1α, GM-CSF, or IL-2 alone does not translate to improved survival. The systemic protective effects afforded by the MIP-1α + IL-2 or MIP-1α + GM-CSF combination are mediated by different effector cell populations. In the MIP-1α + IL-2 group, antineoplastic defense is mediated by CD8+ T and NK cells, whereas in the MIP-1α + GM-CSF group CD4+ T cells are involved in addition to CD8+ cytotoxic T cells, underscoring that T cell help is critical for long-term protection. Thus combination of MIP-1α with different cytokines recruits different sets of effector cells into a potent antineoplastic immune response.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results